PT1378246E - Inibidores da spla2 para a arteriosclerose - Google Patents

Inibidores da spla2 para a arteriosclerose Download PDF

Info

Publication number
PT1378246E
PT1378246E PT02705327T PT02705327T PT1378246E PT 1378246 E PT1378246 E PT 1378246E PT 02705327 T PT02705327 T PT 02705327T PT 02705327 T PT02705327 T PT 02705327T PT 1378246 E PT1378246 E PT 1378246E
Authority
PT
Portugal
Prior art keywords
arteriosclerosis
spla2 inhibitors
treating
group
preventing
Prior art date
Application number
PT02705327T
Other languages
English (en)
Inventor
Kohji Hanasaki
Akihiko Saiga
Takashi Ono
Katsutoshi Yamada
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of PT1378246E publication Critical patent/PT1378246E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT02705327T 2001-03-19 2002-03-19 Inibidores da spla2 para a arteriosclerose PT1378246E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001078569 2001-03-19
JP2001401289 2001-12-28

Publications (1)

Publication Number Publication Date
PT1378246E true PT1378246E (pt) 2009-05-22

Family

ID=26611547

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02705327T PT1378246E (pt) 2001-03-19 2002-03-19 Inibidores da spla2 para a arteriosclerose

Country Status (14)

Country Link
US (1) US20040248898A1 (pt)
EP (2) EP1378246B1 (pt)
JP (1) JP4499361B2 (pt)
KR (1) KR100908968B1 (pt)
CN (1) CN1553814B (pt)
AT (1) ATE428425T1 (pt)
BR (1) BR0208275A (pt)
CA (1) CA2441110C (pt)
DE (1) DE60231969D1 (pt)
ES (1) ES2324766T3 (pt)
MX (1) MXPA03008440A (pt)
PT (1) PT1378246E (pt)
TW (1) TWI314457B (pt)
WO (1) WO2002074342A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2002000621A1 (ja) * 2000-06-29 2004-04-22 塩野義製薬株式会社 Ｘ型ｓＰＬＡ２阻害作用を有する化合物
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
NZ554491A (en) 2004-10-12 2009-07-31 Decode Genetics Ehf Sulfonamide peri-substituted bicyclics for occlusive artery disease
ATE534646T1 (de) 2004-10-29 2011-12-15 Zeria Pharm Co Ltd Carbazolderivat, solvat davon und pharmazeutisch unbedenkliches salz davon
CA2627043A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
MX2008005660A (es) * 2005-11-03 2008-12-15 Ilypsa Inc Compuestos de indol que tienen sustituyentes c4-amida y uso de los mismos como inhibidores de la fosfolipasa a2.
RU2008149518A (ru) 2006-05-16 2010-06-27 Декод Дженетикс, Ехф. (Is) Способ получения 7-(акрилоил) индолов
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
WO2008137803A1 (en) * 2007-05-03 2008-11-13 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies
US20090062369A1 (en) * 2007-08-31 2009-03-05 Joaquim Trias Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels
WO2010038104A1 (en) * 2008-10-03 2010-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event.
NZ789295A (en) 2009-04-29 2024-02-23 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR101037404B1 (ko) * 2010-12-07 2011-05-30 박철형 가변설치가 가능한 압출본체에 의한 천장용 엘이디 조명등

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109309A (en) 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
DE69423436T2 (de) * 1993-06-25 2000-09-07 Smithkline Beecham Plc An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
CZ82295A3 (en) 1994-04-01 1995-12-13 Lilly Co Eli Derivative of 1h-indole-3-glyoxylamide and a pharmaceutical composition containing thereof
US6214876B1 (en) 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
AU3145995A (en) 1994-07-21 1996-02-22 Eli Lilly And Company Indolizine spla2 inhibitors
IL124866A (en) 1995-12-13 2002-08-14 Lilly Co Eli Naphthalide acetamides as sPLA2 inhibitors
JP2000502083A (ja) 1995-12-13 2000-02-22 イーライ・リリー・アンド・カンパニー ｓＰＬＡ▲下２▼インヒビターとしてのナフチルグリオキサミド類
TR199900956T2 (xx) 1996-10-30 1999-07-21 Eli Lilly And Company S�bstit�e edilmi� trisiklik bile�imler.
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
AU3054399A (en) * 1998-03-31 1999-10-25 Shionogi & Co., Ltd. Pyrrolo(1,2-a)pyrazine sPLA2 inhibitor
BR9911048A (pt) * 1998-05-21 2001-02-06 Shionogi & Co Inibidor de spla2 de pirrolo[1,2-b]piridazina
ATE329619T1 (de) * 1998-10-14 2006-07-15 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
WO2001036420A1 (fr) * 1999-11-15 2001-05-25 Shionogi & Co., Ltd. Derives d'aza-indolizine tricyclique ayant un effet inhibiteur sur spla¿2?
JPWO2002000621A1 (ja) * 2000-06-29 2004-04-22 塩野義製薬株式会社 Ｘ型ｓＰＬＡ２阻害作用を有する化合物

Also Published As

Publication number Publication date
TWI314457B (pt) 2009-09-11
EP1378246A1 (en) 2004-01-07
DE60231969D1 (de) 2009-05-28
KR20030085026A (ko) 2003-11-01
CN1553814B (zh) 2010-05-26
US20040248898A1 (en) 2004-12-09
BR0208275A (pt) 2004-04-13
CN1553814A (zh) 2004-12-08
EP1378246A4 (en) 2004-07-07
ES2324766T3 (es) 2009-08-14
EP1378246B1 (en) 2009-04-15
CA2441110A1 (en) 2002-09-26
WO2002074342A1 (fr) 2002-09-26
JP4499361B2 (ja) 2010-07-07
JPWO2002074342A1 (ja) 2004-07-08
KR100908968B1 (ko) 2009-07-22
ATE428425T1 (de) 2009-05-15
EP2044958A2 (en) 2009-04-08
EP2044958A3 (en) 2009-07-08
MXPA03008440A (es) 2004-01-29
CA2441110C (en) 2010-10-12

Similar Documents

Publication Publication Date Title
PT1378246E (pt) Inibidores da spla2 para a arteriosclerose
IL165255A0 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease
NO20093217L (no) Makrocykliske analoger og fremgangsmater for fremstilling og anvendelse derav
DK1569899T3 (da) Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
NO20035327D0 (no) Biologisk aktive metylen-blått derivater
EE200300329A (et) Meetod peroraalselt manustatavate epotiloonide biosaadavuse suurendamiseks ning selles kasutatav komplekt, ravimkoostis ja farmatseutiline ravimvorm
DE60131160D1 (de) Caspase-inhibitoren und ihre verwendungen
ECSP055809A (es) Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4
DE122011100040I1 (de) Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivitat und zur behandlungvon tumoren.
NO20014925L (no) Farmasöytiske forbindelser
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
BR0317520A (pt) Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase
DOP2002000390A (es) Sal citrato de 5,8 14-hiezatetraciclo [10.3.1.0 2,11. 0.4.9] hexadeca-2(11),3,5,8,9, pentaeno y composiciones farmaceuticas de las mismas
ATE339424T1 (de) 3-substituierte 7-alkylidene-3-cephem-4- carbonsäuren als beta-lactamase inhibitoren
NZ502133A (en) Method of enhancing bioavailability of fexofenadine and its derivatives
ATE219085T1 (de) 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren
DE60204611D1 (de) Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
WO2002038563A3 (en) Condensed pyrazindione derivatives as pde inhibitors
AU2157500A (en) Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
ATE258934T1 (de) Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe
WO2002067866A3 (en) Piperazine derivatives as metalloprotease inhibitors
GB0419971D0 (en) Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form
EP1210948B8 (en) Therapeutic peptide for nervous diseases
DE69025817D1 (de) 3-Keto-HMG-CoA Reduktase-Inhibitoren
TH54152A (th) สารยับยั้งชนิด 8-เอริลควิโนลีนฟอสฟอไอเอสเทอเรส-4 ที่ถูกแทนที่